What is the fair value of Evaxion AS (NASDAQ-EVAX) stock?

The current fair value estimate for Evaxion AS (NASDAQ-EVAX) is $4.76. This implies an estimated upside of 45.6% versus the current market price.

Is Evaxion AS (NASDAQ-EVAX) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 45.6% versus the current market price.

What is the analyst price target for NASDAQ-EVAX stock?

The available analyst price target for Evaxion AS (NASDAQ-EVAX) is $11.25. The analyst target implies estimated upside of 244.0%.

How is the financial health of Evaxion AS?

The current financial health read for Evaxion AS (NASDAQ-EVAX) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Evaxion AS's next earnings date?

The next earnings date currently listed for Evaxion AS (NASDAQ-EVAX) is November 19, 2026.

Does Evaxion AS (NASDAQ-EVAX) pay dividends?

The latest available data indicates no current dividend yield for Evaxion AS (NASDAQ-EVAX).

What is the market capitalization of Evaxion AS?

The current market capitalization listed for Evaxion AS is 27.273 M.

What is the enterprise value of Evaxion AS?

The current enterprise value listed for Evaxion AS is 19.877 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Evaxion AS?

The ticker symbol for Evaxion AS is NASDAQ-EVAX, and the stock is listed on NASDAQ.

Where is Evaxion AS (NASDAQ-EVAX) listed?

Evaxion AS (NASDAQ-EVAX) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Evaxion AS?

The current debt-to-total-capital ratio listed for Evaxion AS is 21.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Evaxion AS?

The free float listed for Evaxion AS is 68.1%. Free float helps investors understand how much of the share base is available for public trading.

Evaxion AS (EVAX) Fair Value & Stock Analysis

Evaxion AS (EVAX)

Evaxion Biotech AS is listed on NASDAQ through an ADR, a depositary receipt representing the company’s common stock. The underlying issuer is a clinical-stage biotechnology company focused on AI-powered immunology vaccines. Its pipeline includes EVX-01, a phase 2 candidate being studied globally for advanced melanoma; EVX-03, a DNA-based cancer vaccine for solid tumors; and EVX-04, a therapeutic cancer vaccine in phase 1 development for acute myeloid leukemia. The company also has several pre-clinical vaccine programs, including candidates targeting Staphylococcus aureus skin and soft tissue infections, gonorrhea, a bacterial pathogen linked to recurrent infections, and cytomegalovirus. Founded in 2008 and based in Hørsholm, Denmark, the company was previously known as Evaxion Biotech A/S and adopted the name Evaxion A/S in May 2025.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-EVAX	$4.76	45.6% Upside	Undervalued	$11.25	244.0% Upside	Bargain	Good	0.0%	November 19, 2026	2.8x	3.6x	27.273 M	19.877 M	21.0%	68.1%	-16.9	82.9%